Inebilizumab, an anti-CD19 mAb, and blinatumomab, a bispecific T-cell engager (BiTE) Ab that targets both CD19 and CD3 are currently under evaluation in a clinical trial (NCT06570798) with adult patients with LN [28]. The gene discussed is CD19; the disease is lobular neoplasia.